“…Pfizer identifies a number of economic evaluations that have assumed either a general risk of mortality associated with RA that is independent of disease severity measures 183,192,194,202,238,284,285 or have expressed mortality as dependent on functional status (typically as expressed by HAQ). 171,180,193,198,231,237,286,287 The Pfizer model adopts the former approach, assuming an age-sex-specific standardised mortality ratio from Brennan et al, 183 who report age-and sex-specific standardised mortality ratios for a UK population.…”